A competing risks prescription refill model of compliance and persistence

Value in Health

Volumn 13, Issue 6, 2010, Pages 796-804

  Barron, T Ian ^a   Bennett, Kathleen ^a   Feely, John ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

competing risks; compliance; persistence; prescription refill; statins

Indexed keywords

ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; COMPETING RISKS PRESCRIPTION REFILL MODEL; FEMALE; HEALTH BEHAVIOR; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MODEL; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT REFUSAL;

EID: 77956387809     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00741.x     Document Type: Article

References (55)

1. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008 11 : 44 7.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005 353 : 487 497.
3. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001 26 : 331 342.
4. Tremlett H, Van der Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf 2008 17 : 565 576.
5. Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008 29 : 2083 2091.
6. Metz CA, Lucas KH. Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction. Ann Pharmacother 2001 35 : 496 500.
7. Vrijens B, Belmans A, Matthys K, et al. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf 2006 15 : 115 121.
8. Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2007 11 : 44 7.
9. Halpern MT, Khan ZM, Schmier JK, et al. Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data. Hypertension 2006 47 : 1039 1048.
10. Steiner JF, Gardner EM. Assessing medication adherence from pharmacy records. Pharmacoepidemiol Drug Saf 2006 15 : 575 577.
11. Urquhart J. Pharmionics: research on what patients do with prescription drugs. Pharmacoepidemiol Drug Saf 2004 13 : 587 590.
12. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008 336 : 1114 1117.
13. Andrade SE, Kahler KH, Frech F, Chan K. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006 15 : 565 574. Discussion 75-7.
14. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007 10 : 3 12.
15. Schultz JS, O'Donnell JC, McDonough KL, et al. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care 2005 11 : 306 312.
16. Peterson AM, McGhan WF. Pharmacoeconomic impact of non-compliance with statins. Pharmacoeconomics 2005 23 : 13 25.
17. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007 26 : 2389 2430.
18. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002 288 : 455 461.
19. Gray J, Majeed A, Kerry S, Rowlands G. Identifying patients with ischaemic heart disease in general practice: cross sectional study of paper and computerised medical records. BMJ 2000 321 : 548 550.
20. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997 50 : 105 116.
21. Benner JS, Pollack MF, Smith TW, et al. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm 2005 62 : 1468 1475.
22. Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004 22 (Suppl. 3 13 23.
23. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther 2005 27 : 1639 1646.
24. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005 165 : 1147 1152.
25. Gibson TB, Mark TL, McGuigan KA, et al. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006 12 : 509 517.
26. Abraha I, Montedori A, Stracci F, et al. Statin compliance in the Umbrian population. Eur J Clin Pharmacol 2003 59 : 659 661.
27. Lesaffre E, Kocmanova D, Lemos PA, et al. A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. Clin Ther 2003 25 : 2431 2447.
28. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004 89 : 1117 1123.
29. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007 13 : 559 565.
30. Medical College of Wisconsin GSoBS, Department of Population Health, Division of Biostatistics. SAS Macro for cumulative incidence functions.
31. Andersen PK, Klein JP, Rosthøj S. Generalised linear models for correlated pseudo-observations, with applications to multi-state models. Biometrika 2003 90 : 15 27.
32. Klein JP, Gerster M, Andersen PK, et al. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed 2008 89 : 289 300.
33. Medical College of Wisconsin GSoBS, Department of Population Health, Division of Biostatistics. SAS Macros to find pseudo-values for censored data.
34. Logan BR, Klein JP, Zhang MJ. Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation. Biometrics 2008 64 : 733 740.
35. Klein JP, Andersen PK. Regression modeling of competing risks data based on pseudovalues of the cumulative incidence function. Biometrics 2005 61 : 223 229.
36. Ambrogi F, Biganzoli E, Boracchi P. Clinical useful measures for the study of competing risks in survival analysis. 28th Annual Conference of the International Society for Clinical Biostatistics. Alexandropoulis, Greece, 2007.
37. Rosthøj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004 74 : 69 75.
38. LaFleur J, Thompson CJ, Joish VN, et al. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006 40 : 1274 1279.
39. Cheng CW, Woo KS, Chan JC, et al. Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device. Am J Health Syst Pharm 2005 62 : 411 415.
40. Cheng CW, Woo KS, Chan JC, et al. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol 2004 58 : 528 535.
41. McGinnis B, Olson KL, Magid D, et al. Factors related to adherence to statin therapy. Ann Pharmacother 2007 41 : 1805 1811.
42. Rosen MI, Rigsby MO, Salahi JT, et al. Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 2004 42 : 409 422.
43. Rigsby MO, Rosen MI, Beauvais JE, et al. Cue-dose training with monetary reinforcement: pilot study of an antiretroviral adherence intervention. J Gen Intern Med 2000 15 : 841 847.
44. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997 18 : 1718 1724.
45. Bouchard MH, Dragomir A, Blais L, et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007 63 : 698 708.
46. Perreault S, Dragomir A, Blais L, et al. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008 66 : 706 716.
47. Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008 66 : 110 116.
48. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002 88 : 229 233.
49. Valuck RJ, Williams SA, MacArthur M, et al. A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization. Clin Ther 2003 25 : 2936 2957.
50. Hughes DA, Walley T. Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modeling. Clin Pharmacol Ther 2003 74 : 1 8.
51. Stern RH, Abel RB. Rate of low-density lipoprotein cholesterol and apolipoprotein B changes on initiation and discontinuation of atorvastatin treatment. J Clin Pharmacol 1997 37 : 291 296.
52. Sampietro T, Galetta F, Bionda A. Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Cardiovasc Drugs Ther 1995 9 : 785 789.
53. Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002 144 : 674 677.
54. Colivicchi F, Bassi A, Santini M, et al. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007 38 : 2652 2657.
55. Motheral B, Brooks J, Clark MA, Caltagirone C. A checklist for retrospective database studies - report of the ISPOR Task Force on Retrospective Databases. Value Health 2003 6 : 90 7.